StockNews.AI
SMMT
StockNews.AI
3 hrs

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

1. Portnoy Law Firm is investigating SMMT for potential securities fraud. 2. SMMT saw a significant stock price drop after trial results were released. 3. Further data revealed weaker results for ivonescimab in specific regions. 4. Investors may pursue claims due to alleged corporate wrongdoing. 5. Portnoy Law Firm has a track record of recovering over $5.5 billion.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The investigation into SMMT for securities fraud signals severe trust issues. Historically, similar investigations have resulted in substantial price declines for affected stocks.

How important is it?

The ongoing investigation directly implicates SMMT's financial integrity, affecting investor confidence. Sudden price drops and class action threats provide a high likelihood of impacting SMMT's stock.

Why Short Term?

Legal actions can prompt immediate market reactions, influencing stock prices rapidly. The ongoing investigation may spike volatility in the near future.

Related Companies

PFEJNJAMGN
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.  Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/summit-therapeutics-inc-4/. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses. We are investigating Summit Therapeutics Inc. (SMMT) (“Summit” or the “Company”) for potential violations of the federal securities laws. On May 30, 2025, Summit issued a press release “announc[ing] topline results from the Phase III clinical trial, HARMONi, the first global Phase III study evaluating ivonescimab[.]” Although patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die than patients who received chemo alone, the drug failed to make a statistically significant difference in overall survival, a metric that measures how long patients live before dying of any cause. On this news, Summit’s stock price fell $7.99 per share, or 30.5%, to close at $18.22 per share on May 30, 2025. Then, on September 7, 2025, Summit announced additional data from the trial, in which ivonescimab produced weaker results in patients from North America and Europe than in those from Europe. On this news, Summit’s stock price fell $6.54 per share, or 25.15%, to close at $19.45 per share on September 8, 2025. The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes. Lesley F. Portnoy, Esq.Admitted CA, NY and TX Barlesley@portnoylaw.com310-692-8883www.portnoylaw.com  Attorney Advertising

Related News